Understanding the impacts of COVID-19 pandemic in people with multiple sclerosis treated with ocrelizumab

Mult Scler Relat Disord. 2021 Oct:55:103203. doi: 10.1016/j.msard.2021.103203. Epub 2021 Aug 8.


The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to major challenges in the therapeutic management of patients living with multiple sclerosis (PLwMS), particularly regarding the use of disease-modifying therapies. Despite an extraordinary scientific effort to study SARS-CoV-2 in PLwMS, the heterogeneity of COVID-19 manifestations, immunological mechanisms induced by the natural infection or the vaccines, and the extent of protection through the vaccines, major knowledge gaps remain. Here, we describe the scientific evidence generation plan developed by Roche/Genentech to better understand the impact of the COVID-19 pandemic in PLwMS treated with the B-cell depleting monoclonal antibody ocrelizumab.

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal, Humanized
  • COVID-19*
  • Humans
  • Multiple Sclerosis* / drug therapy
  • Multiple Sclerosis* / epidemiology
  • Pandemics
  • SARS-CoV-2


  • Antibodies, Monoclonal, Humanized
  • ocrelizumab